SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-23-001145
Filing Date
2023-12-13
Accepted
2023-12-13 17:20:02
Documents
2
Group Members
ORBIMED CAPITAL GP VII LLCORBIMED CAPITAL LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 ss2818988_sc13da-keros.htm SC 13D/A 133654
2 JOINT FILING AGREEMENT ss2818988_ex9901.htm EX-99.1 7236
  Complete submission text file 0000947871-23-001145.txt   142452
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91484 | Film No.: 231484947
SIC: 2834 Pharmaceutical Preparations